Results 21 to 30 of about 1,394 (181)

Siltuximab monotherapy improves progression free survival compared to rituximab-based therapies in patients with idiopathic multicentric Castleman disease; indirect comparison of studies using single-arm metanalysis method and the generalized linear mixed model. [PDF]

Ann Hematol
Siltuximab is the only approved treatment for idiopathic multicentric Castleman Disease but in many countries the only available treatment is rituximab based.
Karatisidis L, Mprotsis T, Intzes S, Zagoridis K, Vrachiolias G, Karatisidou V, Bezirgianidou Z, Liapis K, Kotsianidis I, Spanoudakis E.   +9 more
europepmc   +2 more sources

Siltuximab in Idiopathic Multicentric Castleman Disease: Real-World Experience. [PDF]

J Hematol
Castleman disease (CD) is a very rare, non-malignant lymphoproliferative disorder that can be classified as unicentric or multicentric (MCD). MCD is associated with systemic symptoms, including organ dysfunction due to cytokine dysregulation, primarily interleukin-6 (IL-6).
Jitaru C, Symeonidis A, Badelita S, Katodritou E, Colita A, Mpanti A, Bancos A, Tigu B, Rotariu P, Urian L, Rus I, Dima D, Bojan A, Damian M, Labropoulou V, Muresan MS, Fotiou D, Fetica B, Petrushev B, Dascalescu A, Dalampira D, Buruiana S, Constantinescu C, Zdrenghea M, Dimopoulos MA, Tomuleasa C, Terpos E.   +26 more
europepmc   +3 more sources

Computed tomography findings of idiopathic multicentric Castleman disease subtypes. [PDF]

J Clin Exp Hematop
This study retrospectively evaluated the computed tomography (CT) findings of idiopathic multicentric Castleman disease (iMCD) at a single center and compared the CT findings of iMCD-TAFRO with those of iMCD-non-TAFRO. CT images obtained within 30 days before diagnostic confirmation were reviewed for 20 patients with iMCD (8 men and 12 women, mean age ...
Iguchi T, Nishikori A, Sato Y, Nishimura MF, Iwaki N, Kojima K, Asahara T, Otsuka F, Maeda Y, Hiraki T.   +9 more
europepmc   +3 more sources

Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): Factors to differentiate from IgG4-related disease. [PDF]

J Clin Pathol
Nishikori A, Nishimura MF, Fajgenbaum DC, Nishimura Y, Maehama K, Haratake T, Tabata T, Kawano M, Nakamura N, Momose S, Sumiyoshi R, Koga T, Yamamoto H, van Rhee F, Kawakami A, Sato Y.   +15 more
europepmc   +3 more sources

An Unusual Case of HHV-8 Negative, Idiopathic, Multicentric Castleman Disease Following Chronic Lymphocytic Leukaemia. [PDF]

Eur J Case Rep Intern Med
Background: Castleman disease is a rare condition characterised by polytypic lymphocytes proliferation and lymphadenopathy generally with a benign course.
Sansen PY, Vellemans H, Depaus J, Fervaille C, Krug B, Sonet A, Collinge E.   +6 more
europepmc   +2 more sources

Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease [PDF]

Blood, 2018
David C Fajgenbaum
exaly   +2 more sources

Idiopathic Multicentric Castleman Disease Mimicking Orbital Pseudotumor [PDF]

Journal of the Korean Neurological Association, 2020
Sang Hoon Han, Seung-Myoung Son, Sung-Hyun Lee   +2 more
openalex   +2 more sources

Idiopathic multicentric Castleman disease and its rare association with peripheral neuropathy and stroke [PDF]

Clin Med (Lond), 2023
Hatta B, Syafiqah S, Rasheed M, Vegagonzalez M, Leong W, Bashir A.   +5 more
europepmc   +2 more sources

The Evolution and Recent Advances in Diagnostic Criteria for Idiopathic Multicentric Castleman Disease. [PDF]

Am J Hematol
Idiopathic Multicentric Castleman Disease. ABSTRACT Idiopathic multicentric Castleman disease (iMCD) is a rare cytokine‐driven disorder characterized by systemic inflammation, organ dysfunction, and altered lymph node microscopic architecture. Over the past decade, diagnostic criteria have evolved significantly, integrating clinical, histopathological,
Alnoor F, Spies NC, Kumar J, Samghabadi P, Silva O, Luo MX, Chisholm KM, Zhang J, Rangel A, Ng D, Li P, Ohgami RS.   +11 more
europepmc   +2 more sources

Plasma Cell-rich Nephritis with a Systemic Polyclonal Lymphoproliferative Disorder, Mimicking Idiopathic Multicentric Castleman Disease, Systemic Lupus Erythematosus, and IgG4-related Disease. [PDF]

Intern Med
Hebisawa Y, Ohta A, Sekimoto R, Sakurai N, Setoguchi K.   +4 more
europepmc   +3 more sources